Outlook Therapeutics is trading 5.2% down at $1.01 in pre-market as investors lock in short-term gains following a sharp rally driven by regulatory optimism.
- The stock previously surged in after-hours trading on July 27, 2026, after the company received FDA approval for its wet AMD eye injection.
- Shares are currently pulling back modestly as traders reassess valuation and capitalize on the recent price spike.